Abstract
To find new drug candidates for treating Alzheimers disease, we used the similarity search technique and GTS-21 as a template to search the Traditional Chinese Medicines Database. The high-score molecules thus obtained were compared with the template through the flexible alignment. Those molecules which had good alignment with GTS- 21 were selected for conducting the docking studies aimed at the α7 nicotinic acetylcholine receptor. The CHARMM22 force field was taken to compute the partial charge and the TABU search was adopted to operate the docking process. The docking results thus obtained were used to compare with that of GTS-21. Those molecules which had better docking results than that of GTS-21 were singled out for further consideration. Finally, it was found through an in-depth structural analysis that Mol 7235 might be a promising candidate for further modification by experiments to make it become an effective drug for treating Alzheimers disease.
Keywords: Alzheimer's disease, α7 receptor, GTS-21, pharmacophore alignment, docking, traditional chinese medicines database
Medicinal Chemistry
Title: Screening for New Agonists Against Alzheimers Disease
Volume: 3 Issue: 5
Author(s): Huiqin Zheng, Dong-Qing Wei, Rui Zhang, Chunfang Wang, Huachun Wei and Kuo-Chen Chou
Affiliation:
Keywords: Alzheimer's disease, α7 receptor, GTS-21, pharmacophore alignment, docking, traditional chinese medicines database
Abstract: To find new drug candidates for treating Alzheimers disease, we used the similarity search technique and GTS-21 as a template to search the Traditional Chinese Medicines Database. The high-score molecules thus obtained were compared with the template through the flexible alignment. Those molecules which had good alignment with GTS- 21 were selected for conducting the docking studies aimed at the α7 nicotinic acetylcholine receptor. The CHARMM22 force field was taken to compute the partial charge and the TABU search was adopted to operate the docking process. The docking results thus obtained were used to compare with that of GTS-21. Those molecules which had better docking results than that of GTS-21 were singled out for further consideration. Finally, it was found through an in-depth structural analysis that Mol 7235 might be a promising candidate for further modification by experiments to make it become an effective drug for treating Alzheimers disease.
Export Options
About this article
Cite this article as:
Zheng Huiqin, Wei Dong-Qing, Zhang Rui, Wang Chunfang, Wei Huachun and Chou Kuo-Chen, Screening for New Agonists Against Alzheimers Disease, Medicinal Chemistry 2007; 3 (5) . https://dx.doi.org/10.2174/157340607781745492
DOI https://dx.doi.org/10.2174/157340607781745492 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Towards a Clarification of Terminology in Medicine Taking Behavior: Compliance, Adherence and Concordance are Related Although Different Terms with Different Uses
Current Clinical Pharmacology Resveratrol, A Neuroprotective Supplement for Alzheimer's Disease
Current Pharmaceutical Design From the Editors Perspective: Rational Approaches for Radical Entities
Current Neurovascular Research Biochemistry and Neurobiology of Prosaposin: A Potential Therapeutic Neuro-Effector
Central Nervous System Agents in Medicinal Chemistry Current Therapy and Computational Drug Designing Approaches for Neurodegenerative Diseases -with Focus on Alzheimer’s and Parkinson’s.
Current Signal Transduction Therapy The Association of MME microRNA Binding Site Polymorphism with the Risk of Late Onset Alzheimer’s Disease in Northern Han Chinese
Current Neurovascular Research Design, Synthesis and Investigation of New Diphenyl Substituted Pyridazinone Derivatives as Both Cholinesterase and Aβ-Aggregation Inhibitors
Medicinal Chemistry STAT3 and Its Phosphorylation are Involved in HIV-1 Tat-Induced Transactivation of Glial Fibrillary Acidic Protein
Current HIV Research Chemical Analysis of the Chinese Herbal Medicine Turmeric (Curcuma longa L.)
Current Pharmaceutical Analysis Crocetin Attenuates Spatial Learning Dysfunction and Hippocampal Injury in a Model of Vascular Dementia
Current Neurovascular Research The Concept of “Neuroprotection” in Neurological Diseases
Current Neuropharmacology Fibrillar β-Amyloid Impairs the Late Phase of Long Term Potentiation
Current Alzheimer Research Therapeutic Opportunities for Trophic Factors in Brain Inflammation
Current Pharmaceutical Analysis Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry Membrane Interacting Peptides: A Review
Current Protein & Peptide Science Targeting Inhibition of COX-2: A Review of Patents, 2002 - 2006
Recent Patents on Inflammation & Allergy Drug Discovery Increase of EEG Alpha3/Alpha2 Power Ratio Detects Inferior Parietal Lobule Atrophy in Mild Cognitive Impairment
Current Alzheimer Research Alzheimers Disease: Interactions Between Cholinergic Functions and β- amyloid
Current Alzheimer Research Structural Diversity of Neuritogenic Substances and their Application Perspective
Mini-Reviews in Medicinal Chemistry Early Development of Symptomatic Drugs in AD: A Systematic Review of the Use of Biomarkers
CNS & Neurological Disorders - Drug Targets